Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | GPR6 | P46095 | 4/20 | 0.39 |
| ▸ | DPP4 | P27487 | 6/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13859408 | 0.91 | MC4R (0.48) | MC4RGPR6DPP4DPP7DPP8 | |
| SCHEMBL24742095 | 0.80 | PDE2A (0.40) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL90586 | 0.72 | CHRM2 (0.44) | MC4RCHRM3 | |
| SCHEMBL22221062 | 0.72 | IDO1 (0.37) | DPP4DPP8DPP9SLC6A2HSD11B1 | |
| SCHEMBL20811546 | 0.72 | IDO1 (0.37) | DPP4DPP8DPP9SLC6A2HSD11B1 | |
| SCHEMBL90797 | 0.69 | OPRM1 (0.46) | SLC6A2CHRM3 | |
| SCHEMBL14588870 | 0.69 | OPRM1 (0.46) | SLC6A2CHRM3 | |
| SCHEMBL1824241 | 0.68 | GRM2 (0.45) | — | |
| SCHEMBL26397467 | 0.67 | PDE2A (0.38) | — | |
| SCHEMBL28245568 | 0.66 | GPR6 (0.45) | MC4RGPR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129533-B2 | Method for production of quinolone-containing lyophilized preparation | DALICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129533-B2 | Method for production of quinolone-containing lyophilized preparation | DALICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-7875722-B2 | having high antibacterial activity and high safety, at high yield and in a simple manner; one-pot process | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-01-25 | — | — | US | disclosed |
| US-7875722-B2 | having high antibacterial activity and high safety, at high yield and in a simple manner; one-pot process | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-01-25 | — | — | US | disclosed |
| US-20100063279-A1 | METHOD FOR PRODUCING QUINOLONE CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063279-A1 | METHOD FOR PRODUCING QUINOLONE CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-2130827-A1 | METHOD FOR PRODUCING QUINOLONE CARBOXYLIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-20080300403-A1 | Method for Production of Quinolone-Containing Lyophilized Preparation | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-12-04 | — | — | US | disclosed |
| US-20080300403-A1 | Method for Production of Quinolone-Containing Lyophilized Preparation | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-12-04 | — | — | US | disclosed |
| EP-1930006-A1 | METHOD FOR PRODUCTION OF QUINOLONE-CONTAINING LYOPHILIZED PREPARATION | Daiichi Sankyo Company, Limited (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-7176313-B2 | Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176313-B2 | Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300403-A1 | Method for Production of Quinolone-Containing Lyophilized Preparation | NQO2, TREH, CYP51A1 | MC4R 4301/4885GPR6 3591/4885DPP4 2192/4885 |
| US-20100063279-A1 | METHOD FOR PRODUCING QUINOLONE CARBOXYLIC ACID DERIVATIVE | NQO2, QPCT, QARS1 | MC4R 2724/4885GPR6 3075/4885DPP4 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.